Browsing Tag
CNS drug development
4 posts
Will ZEPHYR and IRIS data position MapLight Therapeutics, Inc. as a scalable CNS innovator?
MapLight Therapeutics nears dual CNS data readouts. Discover how ZEPHYR and IRIS could shape its strategy and market positioning.
Why CNS drug developers are paying attention to Alamar Biosciences’ latest move
How Alamar Biosciences’ Neuro 220 Panel could reshape CNS biomarker discovery and drug trials. Explore the strategic implications now.
FDA approves JNJ’s CAPLYTA for depression: Is this a new hope for MDD remission?
Johnson & Johnson secures FDA approval for CAPLYTA in major depressive disorder. Find out how this expands safe treatment options for difficult-to-treat depression.
Why did Newron Pharmaceuticals stock rise by nearly 8% and what triggered investor enthusiasm?
Newron Pharmaceuticals stock rallies 7.88% after evenamide schizophrenia trial data and WCBP presentations highlight breakthrough potential. Read what’s next for investors.